Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
Shen L, Andre T, Chung H, Deeken J, Garralda E, Italiano A, Leyvraz S, Liu T, Burcoveanu D, Grugel R, Mussi C, Xu R, Hong D, Drilon A, Berlin J. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2024, 42: 109-109. DOI: 10.1200/jco.2024.42.3_suppl.109.Peer-Reviewed Original ResearchMicrosatellite-instability-highTreatment-related adverse eventsProgression-free survivalPartial responseNTRK gene fusionsOverall survivalProgressive diseaseGI cancersImmune-oncologyMedian time to responseNext-generation sequencing testSafety of larotrectinibTRK fusion cancerEsophageal squamous cell carcinomaSquamous cell carcinomaTime to responseIO therapyMedian DoRStable diseaseData cutoffGene fusionsGrade 1/2Systemic therapyMedian durationCell carcinoma